 |
 |

High Incidence of Post–Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes
Olaf Stüve, MD, PhD;
Petra D. Cravens, PhD;
Mahendra P. Singh, PhD;
Elliot M. Frohman, MD, PhD;
J. Theodore Phillips, MD, PhD;
Gina Remington, RN, BSN;
Wei Hu, MD, PhD;
Bernhard Hemmer, MD;
Michael J. Olek, DO;
Nancy L. Monson, PhD;
Michael K. Racke, MD
Arch Neurol. 2007;64(7):1055-1056.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
The reported frequency of post–lumbar puncture headache (PLPH) is as high as 70%.1 In contrast, the frequency of PLPH with an atraumatic 22-gauge Sprotte needles is 12.2%.2
Natalizumab (Tysabri; Biogen Idec, Cambridge, Massachusetts) is a recombinant humanized monoclonal antibody that binds to the 4 chain of the 4β1 and 4β7 integrins. Natalizumab reduces the extravasation of T lymphocytes, B lymphocytes, and plasma cells into the central nervous system.3-4 We tested the association between lymphocyte numbers in the peripheral blood and cerebrospinal fluid (CSF) and the frequency of PLPH in patients with relapsing-remitting multiple sclerosis who were receiving natalizumab therapy and 14 months after cessation of therapy.
Methods
Patients
. . . [Full Text of this Article] Lumbar Puncture and Cell Analysis Statistical Analyses Results Patients
Post–Lumbar Puncture Headache Cell Numbers in Peripheral Blood and CSF Comment
AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|